Accupril Clinical Trials and Studies
Buy AccuprilAccupril Information
Accupril Clinical Trials and Studies
Heart Failure
In a placebo-controlled Accupril trial involving patients with congestive heart failure treated with digitalis and diuretics, parenteral quinaprilat, the active metabolite of quinapril, reduced pulmonary capillary wedge pressure, and systemic vascular resistance and increased cardiac output/index. Similar favorable hemodynamic effects were seen with oral quinapril in baseline-controlled trials, and such effects appeared to be maintained during chronic oral quinapril therapy. Accupril reduced renal hepatic vascular resistance and increased renal and hepatic blood flow with glomerular filtration rate remaining unchanged.
A significant Accupril dose response relationship for improvement in maximal exercise tolerance has been observed with quinapril HCl therapy. Beneficial effects on the severity of heart failure as measured by New York Heart Association (NYHA) classification and Quality of Life and on symptoms of dyspnea, fatigue, and edema were evident after 6 months in a double blind, placebo controlled study. Favorable effects were maintained for up to two years of open label therapy. The effects of Accupril on long-term mortality in heart failure have not been evaluated.
Buy Accupril